BioCentury | Jul 19, 2010
Clinical News

Mesendo: Phase I data

...Data were presented at the International Society of Stem Cell Research meeting in San Francisco. TCA Cellular Therapy LLC...
BioCentury | Jan 18, 2010
Clinical News

Mesenchymal stem cells: Phase I started

...TCA began an open-label, U.S. Phase I trial in 6 patients. TCA Cellular Therapy LLC , Covington, La. Product...
BioCentury | Sep 7, 2009
Clinical News

Mesendo: Phase I/II data

...the Phase I portion of the trial were reported in April (see BioCentury, April 6). TCA Cellular Therapy LLC...
BioCentury | Sep 7, 2009
Clinical News

Mesendo: Phase I data

...at 6 months. Data were presented at the European Society of Cardiology Congress in Barcelona. TCA Cellular Therapy LLC...
BioCentury | Apr 6, 2009
Clinical News

Mesendo: Phase I data

...for 12 months. Data were presented at the American College of Cardiology meeting in Orlando. TCA Cellular Therapy LLC...
Items per page:
1 - 5 of 5
BioCentury | Jul 19, 2010
Clinical News

Mesendo: Phase I data

...Data were presented at the International Society of Stem Cell Research meeting in San Francisco. TCA Cellular Therapy LLC...
BioCentury | Jan 18, 2010
Clinical News

Mesenchymal stem cells: Phase I started

...TCA began an open-label, U.S. Phase I trial in 6 patients. TCA Cellular Therapy LLC , Covington, La. Product...
BioCentury | Sep 7, 2009
Clinical News

Mesendo: Phase I/II data

...the Phase I portion of the trial were reported in April (see BioCentury, April 6). TCA Cellular Therapy LLC...
BioCentury | Sep 7, 2009
Clinical News

Mesendo: Phase I data

...at 6 months. Data were presented at the European Society of Cardiology Congress in Barcelona. TCA Cellular Therapy LLC...
BioCentury | Apr 6, 2009
Clinical News

Mesendo: Phase I data

...for 12 months. Data were presented at the American College of Cardiology meeting in Orlando. TCA Cellular Therapy LLC...
Items per page:
1 - 5 of 5